New drug cocktail shows promise in rare colorectal cancer
NCT ID NCT05510895
First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 34 times
Summary
This study tested a combination of three drugs (encorafenib, binimetinib, and cetuximab) given before surgery to people with a specific type of colorectal cancer that has a BRAF V600E mutation. Only 2 patients took part. The goal was to see how much the tumor shrank and to check for side effects. The results help guide future research, but the small size means we cannot draw broad conclusions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hämatologisch-Onkologische Praxis Eppendorf
Hamburg, 20249, Germany
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.